HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haberkorn, U. Articles by van Kaick, G. Search for Related Content PubMed PubMed Citation Articles by Haberkorn, U. Articles by van Kaick, G.

Fluorodeoxyglucose Imaging of Advanced Head and Neck Cancer After Chemotherapy

Institute of Radiology and Pathophysiology, German Cancer Research Center, Im Neuenheimer, University of Heidelberg—Mannheim
Department of Oto-Rhino-Laryngology, University of Heidelberg, Germany

Correspondence: For reprints or correspondence contact: Uwe Haberkorn, MD, Institute of Radiology and Pathophysiology, German Cancer Research Center, Im Neuenheimer Feld 280, D-6900 Heidelberg, Germany.

ABSTRACT

Positron emission tomography (PET) was applied to evaluate therapeutic effects in patients with advanced head and neck cancer for use in monitoring therapy. In 18 patients with histologically proven head and neck cancer, PET studies with 330–440 MBq ¹⁸F-fluorodeoxyglucose (FDG) were performed prior to the first chemotherapeutic cycle with cisplatin and 5-FU. A second examination after the first chemotherapeutic cycle was performed in 11 patients. Tumor or lymph node volumes were determined from CT slices and the growth rate was calculated assuming an exponential function. Uptake in a region of interest was used for the quantitative evaluation of the PET images after standardization to injected dose and body weight. FDG data were available for 6 tumors and 10 metastases, volumetric data for 5 tumors and 7 metastases. One lesion showed an increase, seven a decrease in FDG uptake and eight lesions remained unchanged. Multiple lymph nodes in the same patient showed different baseline metabolisms and also different changes following therapy. Tumors were more sensitive to therapy than lymph node metastases. The growth rate and the change in FDG uptake were highly correlated with different regression functions for tumors and lymph node metastases. These data demonstrate that PET with FOG can be used to assess early chemotherapeutic effects. The information gained with PET can be included for treatment planning in patients undergoing systemic chemotherapy.

This article has been cited by other articles:

				S. K. Mukherji and C. R. Bradford Controversies: Is There a Role for Positron-Emission Tomographic CT in the Initial Staging of Head and Neck Squamous Cell Carcinoma? AJNR Am. J. Neuroradiol., February 1, 2006; 27(2): 243 - 245. [Full Text] [PDF]

				V. Kapoor, M. B. Fukui, and B. M. McCook Role of 18FFDG PET/CT in the Treatment of Head and Neck Cancers: Posttherapy Evaluation and Pitfalls Am. J. Roentgenol., February 1, 2005; 184(2): 589 - 597. [Full Text] [PDF]

				H. Schoder, H. W. D. Yeung, M. Gonen, D. Kraus, and S. M. Larson Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion Radiology, April 1, 2004; 231(1): 65 - 72. [Abstract] [Full Text] [PDF]

				G J R Cook Nuclear medicine in imaging head and neck malignancies Imaging, September 1, 2003; 15(3): 141 - 148. [Abstract] [Full Text] [PDF]

				B. Damascelli, G. L. Patelli, R. Lanocita, G. D. Tolla, L. F. Frigerio, A. Marchiano, F. Garbagnati, C. Spreafico, V. Ticha, C. R. Gladin, et al. A Novel Intraarterial Chemotherapy Using Paclitaxel in Albumin Nanoparticles to Treat Advanced Squamous Cell Carcinoma of the Tongue: Preliminary Findings Am. J. Roentgenol., July 1, 2003; 181(1): 253 - 260. [Abstract] [Full Text] [PDF]

				T. Yoshioka, K. Yamaguchi, K. Kubota, T. Saginoya, T. Yamazaki, T. Ido, G. Yamaura, H. Takahashi, H. Fukuda, and R. Kanamaru Evaluation of 18F-FDG PET in Patients with Advanced, Metastatic, or Recurrent Gastric Cancer J. Nucl. Med., May 1, 2003; 44(5): 690 - 699. [Abstract] [Full Text] [PDF]

				Y. Kitagawa, S. Nishizawa, K. Sano, T. Ogasawara, M. Nakamura, N. Sadato, M. Yoshida, and Y. Yonekura Prospective Comparison of 18F-FDG PET with Conventional Imaging Modalities (MRI, CT, and 67Ga Scintigraphy) in Assessment of Combined Intraarterial Chemotherapy and Radiotherapy for Head and Neck Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 198 - 206. [Abstract] [Full Text] [PDF]

				S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]

				Y. Anzai, S. Minoshima, G. T. Wolf, and R. L. Wahl Head and Neck Cancer: Detection of Recurrence with Three-dimensional Principal Components Analysis at Dynamic FDG PET Radiology, July 1, 1999; 212(1): 285 - 290. [Abstract] [Full Text]

				O. S. AAssar, N. J. Fischbein, G. R. Caputo, M. J. Kaplan, D. C. Price, M. I. Singer, W. P. Dillon, and R. A. Hawkins Metastatic Head and Neck Cancer: Role and Usefulness of FDG PET in Locating Occult Primary Tumors Radiology, January 1, 1999; 210(1): 177 - 181. [Abstract] [Full Text]

				L. G. Strauss Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology Oncologist, December 1, 1997; 2(6): 381 - 388. [Abstract] [Full Text] [PDF]